Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2024

Genmab — Januar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #1155

    Novel Cervical Cancer Treatments in Clinical Trial https://news.med.miami.edu/novel-cervical-cancer-treatments-in-clinical-trial/ “The antibody drug conjugate tisotumab vedotin-tftv has also gained approval and became a standard-of-care therapy this year. This therapy extends survival significantly,” said Dr. Sinno.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #1156

      Pfizer
      earnings later today will give us full year Tiso sales

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #1157

        Tivdak had list price changes this year of 3,90% 30-3-2023
        and 3,90%
        28-9-2023

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #1158

          so, pfizer reports $4mn for Tivdak under Represents revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023. So now we have to find the remainder of the quarter 4 sales somewhere lol, Seagen doesn't report anymore

          1 Reply Last reply
          0
          • M Offline
            M Offline
            M_T_A
            wrote on sidst redigeret af
            #1159

            Pfizer skriver at FDA har accepteret Tivdak sBLA ansøgning om konvertering fra "accelerated approval" til fuld godkendelse med priority review og PDUFA dato d. 9 maj, se link side 8. 2024.https://s28.q4cdn.com/781576035/files/doc_financials/2023/q4/Q4-2023-PFE-Earnings-Release.pdf

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #1160

              Håber det giver himmelfart til kursen 🙂

              1 Reply Last reply
              0
              • P Offline
                P Offline
                Plimsoller
                wrote on sidst redigeret af
                #1161

                Svar fra Andrew Carlsen angående stilleperioden "Our quiet period before earnings is still 2 weeks and has not been extended to 4 weeks with the US listing."

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1162

                  thanks Plimsoller

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    Plimsoller
                    wrote on sidst redigeret af
                    #1163

                    You are welcome.

                    1 Reply Last reply
                    0
                    • JørgenVarnæsJ Offline
                      JørgenVarnæsJ Offline
                      JørgenVarnæs
                      wrote on sidst redigeret af
                      #1164

                      Egentlig en meget subtil måde at spørge “hvad f#€&”€en i h#€”&€&€lvede foregår der!?”

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #1165

                        Maybe not a good sign:

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #1166

                          The third Pfizer product to hit the reject pile is PF-07260437, a phase 1 therapy designed to treat advanced breast cancer, ovarian cancer or endometrial cancer. The B7-H4 x CD3 bispecific monoclonal antibody was being tested among 30 patients in a study that wrapped in October of last year, as listed on ClinicalTrials.gov.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #1167

                            Just a moment...

                            favicon

                            (www.fiercebiotech.com)

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #1168

                              Godt eller dårligt? En konkurrent mindre eller går gen1047 samme vej?

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #1169

                                This decision was not due to major safety concerns (fra Clinical Trials)https://classic.clinicaltrials.gov/ct2/show/NCT05067972

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #1170

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #1171

                                    Dagens regnskaber: https://www.proinvestor.com/finanskalender

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Stroka
                                      wrote on sidst redigeret af
                                      #1172

                                      God morgen 🙂

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #1173

                                        Nej det er jo ikke til at vide, om Pfizers fejlskud her stiller Genmab dårligere eller bedre, men man bør da altid skrive sig bag øret, hvis BP fejler mod samme target.

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #1174

                                          Ja lød semi optimistisk på JP Morgan omkring dette - men fremhævede jo også problemer for både T-cell engagers og CAR-T i solide tumorer, så det er jo allerde svært. Omvendt er de igennem dosis opskalering og nu i gang med expansion - og Jan sagde at safety var ok og de havde set tegn på effekt.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper